{"schema_version":"secwatch.filing_event.v1","accession":"0001534969-22-000122","form_type":"8-K","ticker":"SERA","cik":"0001534969","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.090707+00:00","generated_at":"2026-06-24T01:24:12.917412+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sera Prognostics Q2 net loss widens to $11.5M; cash runway extended to 2026","bullets":["Revenue of $78K, up from $20K in Q2 2021, but operating expenses rose to $11.8M from $7.4M.","Net loss of $11.5M ($0.29/share) vs $6.3M a year ago; cash & securities at $121M as of June 30.","PreTRM test now collects blood at 18-20 weeks; sensitivity ~90%, NPV 99% for preterm risk.","Company streamlined operations to fund operations into 2026 without additional financing.","Contracted several new self-insured employer plans for PreTRM testing as an advanced pregnancy benefit."],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-22-000122","json":"https://secwatch.observer/filing/0001534969-22-000122.json","markdown":"https://secwatch.observer/filing/0001534969-22-000122.md","text":"https://secwatch.observer/filing/0001534969-22-000122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496922000122/0001534969-22-000122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496922000122/sera-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:24:12.917412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}